[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 367
Citations 0
News From the Food and Drug Administration
September 1, 2015

Treatment for HCV Genotypes 3 and 4

JAMA. 2015;314(9):867. doi:10.1001/jama.2015.10492

The FDA has approved 2 new medications to treat 2 different hepatitis C virus (HCV) genotypes without coadministered interferon.

For patients with genotype 3 HCV infection, who comprise about 10% of the 2.7 million US residents infected with the virus, daclatasvir is approved to use in combination with sofosbuvir. In a trial involving 152 patients with chronic genotype 3 HCV infection, 98% of treatment-naive patients with no cirrhosis of the liver had sustained virologic response: no virus was detected in their blood 12 weeks after completing combination treatment (http://1.usa.gov/1VFlkaX).

First Page Preview View Large
First page PDF preview
First page PDF preview